Sunshine Biopharma reports revenue growth for 2025 amid strategic generic expansion
Sunshine Biopharma (NASDAQ:SBFM) has filed its Form 10-K for the fiscal year ended December 31, 2025, reporting a steady increase in top-line revenue alongside a significant expansion of its generic drug portfolio.










